Assessing the cost-effectiveness of withdrawing growth hormone treatment after mid-puberty in adolescents with idiopathic isolated growth hormone deficiency

Assessing the cost-effectiveness of withdrawing growth hormone treatment after mid-puberty in adolescents with idiopathic isolated growth hormone deficiency - Withdrawing growth hormone treatment after mid-puberty

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON55366

Enrollment

128

Registered

2016-10-26

Start date

2017-04-19

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth hormone deficiency

Interventions

The intervention is withdrawing growth hormone treatment in mid-pubertal adolescents with adequate growth hormone secretion at retesting. At the start of growth hormone treatment growth hormone secr

Eligibility

Age

12 Years to 17 Years

Inclusion criteria

Inclusion criteria: GH treated adolescents with partial idiopathic isolated GH deficiency (IIGHD) GH peak at diagnosis >5 mU/L and 12 ml and bone age 13-16 years; girls: Tanner stage B3 or B4 and bone age 11-14 years) GH peak of > 20 mU/L at retesting in mid-puberty GH treatment for at least 3 years Informed consent

Exclusion criteria

Exclusion criteria: Medical or psychologic disorder, or medication other than GH, that could potentially influence growth

Design outcomes

Primary

Measure	Time frame
Primary: adult height (AH) minus target height (TH) SDS. Secondary: adult height SDS, total pubertal growth (cm), and satisfaction with attained adult height.	—

Secondary

Measure	Time frame
Secondary: adult height SDS, total pubertal growth (cm), and satisfaction with attained adult height.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 7, 2026